pharma · Duchenne Muscular Dystrophy · Muscular Dystrophy, Duchenne · SRPT
Sarepta Therapeutics
Sarepta Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker SRPT. Primary therapeutic focus areas include Duchenne Muscular Dystrophy, Muscular Dystrophy, Duchenne, Duche
215 First Street, Cambridge, MA 02142, US HQ
1,150 Employees
Public company Type
SRPT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 215 First Street, Cambridge, MA 02142, US
- Employees
- 1,150
- Programs
- 46
- Drugs
- 23
- Patents
- 102
Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]
Approved · small molecule · Duchenne Muscular Dystrophy
Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] for Duchenne Muscular Dystrophy is a Approved program (small_molecule) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 19-06-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sarepta Therapeutics
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Duchenne Muscular Dystrophy
- Status
- terminated
- Trials
- 1